CervoMed presents neflamapimod trial data
- CervoMed (NASDAQ:CRVO) will present Phase 2a trial biomarker data for neflamapimod at the ISFTD Annual Meeting in October 2026.
- The presentation will include initial results from plasma biomarkers NfL and GFAP from at least 22 participants.
- The trial evaluated safety, pharmacokinetics, and clinical effects of neflamapimod in nonfluent variant primary progressive aphasia patients.
CervoMed (NASDAQ:CRVO) announced that neflamapimod will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias Annual Meeting in October 2026.
The presentation will include biomarker data from the company’s Phase 2a clinical trial evaluating neflamapimod in patients with nonfluent variant primary progressive aphasia.
The abstract accepted for presentation includes 12-week biomarker data from the trial’s first eight participants, with the upcoming presentation expected to highlight results from at least 22 study participants.
CervoMed is developing neflamapimod, an oral small molecule drug candidate designed to target disease processes associated with degenerative brain disorders.
The Phase 2a trial enrolled 25 participants and is being conducted at academic medical centers in the United States and United Kingdom to evaluate safety, pharmacokinetics, and clinical effects.
